Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Effect of IL-21 treatment concurrent to ART and 3HP in Mtb/SIV co-infection

Award Number: R56AI184089
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2024
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

Effect of IL-21 treatment concurrent to ART and 3HP in Mtb/SIV co-infection - Abstract The global control of TB is compounded by co-infection with HIV. Those infected with HIV are at high risk of reactivating latent TB infection (LTBI). Decades of research has not yielded a successful vaccine for the TB/HIV syndemic. While therapeutics control Mycobacterium tuberculosis (Mtb) and HIV burden, they have a potential disadvantage of selecting for resistance and not rescuing from the immune dysfunction. Targeting the host immune response via a host-directed immunotherapy (HDT) provides an opportunity to augment immunity during the short-window of acute HIV-1 co-infection of Mtb. Treatment of LTBI in people living with HIV (PLHIV) reduces the risk of active TB by only 35% and is dependent on the CD4 counts at the time of initiation. Though combinatorial antiretroviral therapy (cART) concurrently given with anti-TB therapy improves the clinical and microbiological parameters, it leads to insufficient reconstitution of protective TH1, TH17 and CD4+ TEM levels in the lungs and fails to rescue from virus-driven immune activation. Additionally, the long-term sterilization of bacteria and immune reconstitution in the lungs has not been shown in the individuals treated concurrently with cART and 3HP. HIV infection depletes IL-21 producing CD4+ T cells and cART only partially restores IL-21 in humans. We hypothesize that supplementing cART and once-weekly, three-month isoniazid and rifapentine (3HP) treatment with IL-21-IgFc fusion protein in Mtb/SIV co-infection will result in a long-term reconstitution of TH1 response and functional CD4+T effector memory (TEM) response in the lung. Further, IL-21-IgFc fusion protein adjunctive to cART and 3HP, will augment cytotoxic function of NK cells, thus significantly reducing the likeliness of LTBI reactivation in Mtb/SIV co-infection. Hence, we aim to explore a HDT that utilizes IL-21-IgFc fusion protein supplementation of cART+3HP to mitigate virus-driven immune dysregulation and thus reduce incidence of LTBI reactivation. By concurrently treating Mtb/SIV co-infected macaques with cART+3HP+IL-21-IgFc fusion protein, our goal is to significantly reduce LTBI reactivation by providing long-term immune reconstitution concurrent to bacterial control by i) induction of an adequate TH1 response via STAT1, ii) generation of CD4+ TEM cells, iii) maintenance of TH17 responses via STAT3 and iv) promotion of cytotoxic function of NK cells. The significance of our novel, translational approach is underscored by our strong preliminary data, and a reproducible, human-like model system. The data from the proposed study will be critical to the development of an immune-based intervention along with cART and anti-TB therapy to control dysregulated immune responses generated during early events of HIV co-infection of LTBI and provide long-term immune reconstitution. This will lead to the future clinical testing of such host-directed therapeutic approaches to control TB/HIV co-infection related mortality and morbidities.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	TEXAS BIOMEDICAL RESEARCH INSTITUTE	8715 W MILITARY DR	SAN ANTONIO	TX	78227	BEXAR	USA	Allergy and Infectious Diseases Research	000	1	8/8/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $718,758 )
2024	2024	TEXAS BIOMEDICAL RESEARCH INSTITUTE	8715 W MILITARY DR	SAN ANTONIO	TX	78227	BEXAR	USA	Allergy and Infectious Diseases Research	000	1	8/28/2024	NEW	$718,758
														Subtotal = $718,758

Grand Total All Awards = $718,758

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Effect of IL-21 treatment concurrent to ART and 3HP in Mtb/SIV co-infection

Award Number: R56AI184089

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2024

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer